William Berry, Jr. Sells 1,953 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) CAO William Berry, Jr. sold 1,953 shares of Stryker stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Stryker Stock Down 0.2%

Shares of NYSE:SYK opened at $359.53 on Wednesday. The firm has a market capitalization of $137.49 billion, a P/E ratio of 47.62, a P/E/G ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a 50 day moving average price of $370.62 and a 200-day moving average price of $381.03. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Stryker by 0.8% during the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after purchasing an additional 272,828 shares in the last quarter. State Street Corp raised its position in Stryker by 1.0% in the 2nd quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after buying an additional 150,204 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after acquiring an additional 79,654 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SYK shares. Evercore ISI lowered their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Rothschild & Co Redburn began coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price for the company. Royal Bank Of Canada restated an “outperform” rating and issued a $435.00 price target on shares of Stryker in a research note on Friday. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Truist Financial boosted their target price on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a report on Friday, November 14th. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.